<p>Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON - 获取免费报告）在周六的午盘交易中创下了新的 52 周高点。该股最高交易价格为 29.80 美元，最后交易价格为 28.90 美元，成交量为 966326 股。该股此前收盘价为 24.12 美元。</p>
<p>获取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师对该股发布了报告。HC Wainwright 将 Eton Pharmaceuticals 的目标股价从 37.00 美元上调至 52.00 美元，并在 3 月 20 日的研究报告中给予该公司 “买入” 评级。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 Eton Pharmaceuticals 的 “卖出（d-）” 评级。Zacks Research 在 4 月 17 日的研究报告中将 Eton Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。B. Riley Financial 在 3 月 20 日的研究报告中将 Eton Pharmaceuticals 的目标价从 26.00 美元上调至 31.00 美元，并给予该股 “买入” 评级。最后，华尔街 Zen 在 3 月 21 日的研究报告中将 Eton Pharmaceuticals 的评级从 “持有” 上调至 “买入”。三位股票研究分析师给予该股 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Eton Pharmaceuticals 的共识评级为 “持有”，共识目标价为 39.33 美元。</p>
<p><strong>查看我们对 ETON 的最新分析</strong></p>
<h2>Eton Pharmaceuticals 股票表现</h2>
<p>该公司的债务与股本比率为 0.83，流动比率为 1.57，速动比率为 1.17。该公司的 50 日移动平均价格为 21.94 美元，200 日移动平均价格为 18.48 美元。该公司的市值为 7.907 亿美金，市盈率为-160.55，贝塔值为 0.82。</p>
<p>Eton Pharmaceuticals（纳斯达克代码：ETON - 获取免费报告）在 3 月 19 日星期四发布了季度财报。该公司报告每股收益为 0.05 美元，低于共识预期的 0.12 美元（差额为 0.07 美元）。Eton Pharmaceuticals 的股本回报率为-2.60%，净利润率为-5.75%。该公司季度收入为 2128 万美元，而分析师预期为 2058 万美元。平均而言，股票研究分析师预计 Eton Pharmaceuticals, Inc.在当前财年将发布 0.82 美元的每股收益。</p>
<h2>机构投资者对 Eton Pharmaceuticals 的看法</h2>
<p>大型投资者最近买入和卖出了该股的股份。阿拉斯加州财政部在第三季度新购入 Eton Pharmaceuticals 的股份，价值 30,000 美元。Quarry LP 在第三季度新购入 Eton Pharmaceuticals 的股份，价值 37,000 美元。凯通国际资产管理有限公司在第四季度新购入 Eton Pharmaceuticals 的股份，价值 44,000 美元。Legal &amp; General Group Plc 在第二季度新购入 Eton Pharmaceuticals 的股份，价值 41,000 美元。最后，中国泛海资产管理有限公司在第四季度新购入 Eton Pharmaceuticals 的股份，价值 74,000 美元。目前 27.86% 的股份由机构投资者和对冲基金持有。</p>
<h2>关于 Eton Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Eton Pharmaceuticals, Inc.是一家专注于开发、生产和商业化针对罕见和被忽视疾病的仿制药和专有药品的专业制药公司。公司总部位于佛罗里达州西棕榈滩，利用其在激素疗法和复杂分子方面的专业知识，解决患者需求高而竞争有限的治疗领域。自 2016 年成立以来，Eton 一直致力于建立一个多元化的产品组合，将成熟的仿制药与针对性的品牌产品相结合。</p>
<p>该公司的产品线包括甲状腺激素替代品，如干燥甲状腺和利奥甲状腺素，以及用于弓形虫病的吡美莫司片。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Eton Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Eton Pharmaceuticals 吗？</h2>
<p>在你考虑 Eton Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Eton Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eton Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ETON

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

<p>Eton Pharmaceuticals（纳斯达克代码：ETON）达到了新的 12 个月高点 29.80 美元，收盘价为 28.90 美元，交易量显著。分析师的评级各不相同：HC Wainwright 将其目标价上调至 52 美元（买入），而 Weiss Ratings 维持卖出评级。该公司报告的收入为 2128 万美元，但未能达到每股收益预期。机构投资者持有 27.86% 的股份。Eton 专注于开发针对罕见疾病的药品，市值为 7.907 亿美金</p>

<p>Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as $29.80 and last traded at $28.90, with a volume of 966326 shares trading hands. The stock had previously closed at $24.12.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON - 获取免费报告）在周六的午盘交易中创下了新的 52 周高点。该股最高交易价格为 29.80 美元，最后交易价格为 28.90 美元，成交量为 966326 股。该股此前收盘价为 24.12 美元。</p>
</div><p>Get <strong>Eton Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts have issued reports on the stock. HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, March 20th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research cut shares of Eton Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, April 17th. B. Riley Financial increased their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. Finally, Wall Street Zen upgraded shares of Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eton Pharmaceuticals has a consensus rating of &#34;Hold&#34; and a consensus target price of $39.33.</p>
<div class="lb-trans"><p>几位股票分析师对该股发布了报告。HC Wainwright 将 Eton Pharmaceuticals 的目标股价从 37.00 美元上调至 52.00 美元，并在 3 月 20 日的研究报告中给予该公司 “买入” 评级。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 Eton Pharmaceuticals 的 “卖出（d-）” 评级。Zacks Research 在 4 月 17 日的研究报告中将 Eton Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。B. Riley Financial 在 3 月 20 日的研究报告中将 Eton Pharmaceuticals 的目标价从 26.00 美元上调至 31.00 美元，并给予该股 “买入” 评级。最后，华尔街 Zen 在 3 月 21 日的研究报告中将 Eton Pharmaceuticals 的评级从 “持有” 上调至 “买入”。三位股票研究分析师给予该股 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Eton Pharmaceuticals 的共识评级为 “持有”，共识目标价为 39.33 美元。</p>
</div><p><strong>View Our Latest Analysis on ETON</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ETON 的最新分析</strong></p>
</div><h2>Eton Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.83, a current ratio of 1.57 and a quick ratio of 1.17. The company's 50-day moving average price is $21.94 and its two-hundred day moving average price is $18.48. The company has a market capitalization of $790.70 million, a price-to-earnings ratio of -160.55 and a beta of 0.82.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.83，流动比率为 1.57，速动比率为 1.17。该公司的 50 日移动平均价格为 21.94 美元，200 日移动平均价格为 18.48 美元。该公司的市值为 7.907 亿美金，市盈率为-160.55，贝塔值为 0.82。</p>
</div><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%.The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. On average, equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（纳斯达克代码：ETON - 获取免费报告）在 3 月 19 日星期四发布了季度财报。该公司报告每股收益为 0.05 美元，低于共识预期的 0.12 美元（差额为 0.07 美元）。Eton Pharmaceuticals 的股本回报率为-2.60%，净利润率为-5.75%。该公司季度收入为 2128 万美元，而分析师预期为 2058 万美元。平均而言，股票研究分析师预计 Eton Pharmaceuticals, Inc.在当前财年将发布 0.82 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Eton Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Eton Pharmaceuticals 的看法</h2>
</div><p>Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new stake in Eton Pharmaceuticals in the third quarter worth $30,000. Quarry LP acquired a new stake in Eton Pharmaceuticals in the third quarter worth $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $44,000. Legal &amp; General Group Plc acquired a new stake in Eton Pharmaceuticals in the second quarter worth $41,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $74,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该股的股份。阿拉斯加州财政部在第三季度新购入 Eton Pharmaceuticals 的股份，价值 30,000 美元。Quarry LP 在第三季度新购入 Eton Pharmaceuticals 的股份，价值 37,000 美元。凯通国际资产管理有限公司在第四季度新购入 Eton Pharmaceuticals 的股份，价值 44,000 美元。Legal &amp; General Group Plc 在第二季度新购入 Eton Pharmaceuticals 的股份，价值 41,000 美元。最后，中国泛海资产管理有限公司在第四季度新购入 Eton Pharmaceuticals 的股份，价值 74,000 美元。目前 27.86% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>About Eton Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Eton Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc.是一家专注于开发、生产和商业化针对罕见和被忽视疾病的仿制药和专有药品的专业制药公司。公司总部位于佛罗里达州西棕榈滩，利用其在激素疗法和复杂分子方面的专业知识，解决患者需求高而竞争有限的治疗领域。自 2016 年成立以来，Eton 一直致力于建立一个多元化的产品组合，将成熟的仿制药与针对性的品牌产品相结合。</p>
</div><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p>
<div class="lb-trans"><p>该公司的产品线包括甲状腺激素替代品，如干燥甲状腺和利奥甲状腺素，以及用于弓形虫病的吡美莫司片。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eton Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Eton Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Eton Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Eton Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Eton Pharmaceuticals 并不在名单上。</p>
</div><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eton Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Eton Pharmaceuticals (NASDAQ:ETON) Reaches New 12-Month High  - Time to Buy?

Market Beat

Eton Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

Legal & General Group Plc

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Eton Pharmaceuticals（NASDAQ:ETON）创下新的 12 个月高点 - 现在是买入的好时机吗？